We present a comprehensive ancestry-based prevalence and co-alteration landscape of genomic alterations and immunotherapy-associated biomarkers in patients withand-altered non-squamous (non-Sq) NSCLC.was the most frequently altered oncogene in European (EUR) and African (AFR), whilealterations ...
R. et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: primary analysis of the LUMINOSITY trial. J. Clin. Oncol. 42, 103–103 (2024). Article Google Scholar Passaro, A., Jänne, P. A. & Peters,...
Moreover, the MET status in non-squamous NSCLC tumor areas showed highly heterogeneous among various histotypes, hindering the adequate patient selection for MET-targeted therapies[12]. The intratumor heterogeneity referred to subclonal diversities of tumor cells was observed in this study. The ...
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.What are the subtypes of NSCLC?Squamous cell carcinoma is found in cells that line the airways of the lungs. It is usually found in the middle of the lung. Adenocarcinoma is found in cells that produce mucus. It...
Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) (see the image below), and large cell carcinoma. [1] Patients with NSCLC require a complete staging workup to evaluate the...
Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways. The three most common forms of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcino...
Further, the PFS at 24 weeks was only 14% in patients with EGFR mutation versus 51% in wild-type NSCLC, respectively.9 Study CA209-153 is a phase 3b/4 safety trial of nivolumab in patients with advanced or metastatic squamous or non-squamous NSCLC who received at least one prior line....
Non-small cell lung cancer (NSCLC) ○ Accounts for 85% of all lung cancers ○ Group of lung cancers arising from secretory cells – Squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and adenocarcinoma in situ ○ Most common appearance is irregular mass in bronchus or lung parenchyma...
VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed ... S Lu,L Wu,H Jian,... 被引量: 0发表: 2022年 Phase III study of afatinib or cisplatin plus pemetrexed in patients with ...
Interpretation Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. This finding is being further explored in an ongoing international, randomised, double-blind, phase 3 study. Funding ...